Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting

BACKGROUND: HCV protease inhibitors (PIs) boceprevir and telaprevir in combination with PEG-Interferon alfa and Ribavirin (P/R) is the new standard of care in the treatment of chronic HCV genotype 1 (GT1) infection. However, not every HCV GT1 infected patient is eligible for P/R/PI therapy. Furtherm...

Descripción completa

Detalles Bibliográficos
Autores principales: Maasoumy, Benjamin, Port, Kerstin, Markova, Antoaneta Angelova, Serrano, Beatriz Calle, Rogalska-Taranta, Magdalena, Sollik, Lisa, Mix, Carola, Kirschner, Janina, Manns, Michael P., Wedemeyer, Heiner, Cornberg, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562338/
https://www.ncbi.nlm.nih.gov/pubmed/23383319
http://dx.doi.org/10.1371/journal.pone.0055285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562338/
https://www.ncbi.nlm.nih.gov/pubmed/23383319
http://dx.doi.org/10.1371/journal.pone.0055285

Ejemplares similares